United States

AFFO (TTM)

AFFO/share (TTM)

AFFO/share Guidance

AFFO (Quarter)

AFFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/AFFO

Size (ft²)

Occupancy

The Company is a fully integrated REIT primarily focused on the ownership, acquisition, development and management of
retail properties net leased to industry leading tenants.

Agree Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, ADC is classified as investment grade

Period: 2022 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Adjusted FFO

Adjusted FFO Growth

Assessment of recent increases in Adjusted FFO per share, indicating profitability

Adjusted FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LAUSANNE, Switzerland , Oct. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in three upcoming investor conferences in November: Stephens Biotechnology Virtual Fireside Chats 2025Date: November 3, 2025 Presentation Time: 12:00 p.m. ET Format: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerLocation: Virtual There will not be a replay or transcript of the call.

ADC Therapeutics to Present at November Investor Conferences

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly known as ZL-1310, (NCT06179069) demonstrating robust and durable responses in heavily pre-treated patients with extensive-stage small cell lung cancer (ES-SCLC). This data will be presented as an oral presentation and was included as part of the press program at the AACR-NCI-EORTC International Con.

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce that it will present new scientific data highlighting the performance of its Accum® technology in enhancing the efficacy of antibody-drug conjugates (ADCs) at the 16th World ADC Conference in San Diego, CA, USA. Defence's proprietary Accum® platform is engineered to improve intracellular delivery and endosomal escape of therapeutic payloads, addressing a critical limitation of current ADCs and enabling higher potency with reduced off-target toxicity.

Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended September 30, 2025. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Third Quarter 2025 Financial and Operating Highlights: Invested approximately $451 million in 110 retail net lease properties across all three external growth platforms Commenced five development or Developer Funding Platform (“DFP”) projects.

Agree Realty Corporation Reports Third Quarter 2025 Results

Most investors have probably never heard of Agree Realty (ADC 0.77%). However, you might have spent some time in one of the real estate investment trust's (REIT) properties before.

Meet the Little-Known Company Yielding 4.2% That Continues to Deliver Monthly for Income Seekers and Is Making Patient Investors Notably Richer

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.262 per common share, representing a 2.3% month-over-month increase. The monthly dividend reflects an annualized dividend amount of $3.144 per common share, representing a 3.6% increase over the annualized dividend amount of $3.036 per common share from the fourth quarter of 2024. The divid.

Agree Realty Declares Increased Monthly Common Dividend

LAUSANNE, Switzerland , Oct. 13, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million private investment in public equity ("PIPE") financing. In the PIPE, ADC Therapeutics is selling 11.3 million common shares at $4.00 per share and pre-funded warrants to purchase 3.8 million common shares at $3.90 per pre-funded warrant, which is the price per common share in the PIPE minus the exercise price of CHF 0.08 per pre-funded warrant.

ADC Therapeutics Announces $60 Million Private Placement

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio with four late-breaking presentations from more than 20 abstracts at the 2025 European Society for Medical Oncology (#ESMO25) Congress. Data at ESMO will spotlight the company's advances towards creating new standards of care for patients with breast cancer, including back-to-back presentations during Presidential Symposium I featurin.

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO

BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed two new provisional patent applications with the United States Patent and Trademark Office (USPTO). The first application includes claims protecting Akari's novel immuno-oncology payload, PH1 (a novel Thailanstatin analog), and its spliceosome modulatory mechanism of action, which is expected to provide a therapeutic benefit by activating the host immune system in the fight against cancer. The second patent filing includes claims for a combination therapy of PH1 pipeline ADCs with other immuno-oncology drugs that alleviate checkpoint inhibition and have demonstrated synergy with immune checkpoint inhibitors (ICIs) in preclinical models. These new patent applications are part of a growing patent portfolio strategy designed to further extend Akari's proprietary position with respect to the Company's novel PH1 payload. These filings also build upon Akari's recent provisional patent filing in late September covering the use of Akari's ADC platform to target cancer by modulating alternative splicing drivers within cancer cells.

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

MILPITAS, Calif.--(BUSINESS WIRE)-- #ADC--Omni Design Technologies, a leading provider of high-performance, low-power Wideband Signal Processing™ solutions, today announced the tape out of its new ODT-ADS-7B64G-3T, an ultra-high-speed 64 GSPS SWIFT™ analog-to-digital converter (ADC) supporting 7- and 8-bit output modes, designed in TSMC's 3nm process. This time-interleaved ADC provides the breakthrough speed and performance required for the next generation of high-speed data communications, including.

Omni Design Technologies Tapes Out Ultra-High-Speed 64GSPS ADC on TSMC N3 process

LAUSANNE, Switzerland , Oct. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 162,000 of the Company's common shares to four new employees on October 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its third quarter 2025 operating results after the market closes on Tuesday, October 21, 2025. A conference call to discuss the Company's operating results is scheduled for Wednesday, October 22, 2025 at 9:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (800) 715-9871 International (646) 307-19.

Agree Realty Announces Third Quarter 2025 Earnings Release Date and Conference Call Information

– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of investigational Pivekimab sunirine (PVEK) for treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

Most stocks pay quarterly dividends, which is fine for many shareholders who reinvest dividends.

5 of Our Favorite High-Yield Stocks Pay Monthly Dividends

Many companies pay dividends, and most of them make quarterly payments. However, some make monthly payouts, making them ideal for those seeking to generate passive income.

4 Monthly Dividend Stocks Yielding 4% or More to Buy Right Now for Passive Income

Data highlights ability of Akari's ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

While reaching retirement age can be both a blessing and a curse, relying on the U.S.

5 Safe Monthly Pay Dividend Stocks Offering Boomers a Lifetime of Income

BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering the Company's antibody drug conjugate (ADC) platform using Akari's spliceosome payload PH1 for treating cancer by modulating alternative splicing within cancer cells. This patent application represents a new patent family to further extend Akari's proprietary position with respect to the Company's novel payload, PH1 (a novel Thailanstatin analog).

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

While reaching retirement age can be both a blessing and a curse, relying on the U.S. government to provide for your needs is not the best idea. The full retirement age is 66 if you were born from 1943 to 1954. The full retirement age increases gradually for those born from 1955 to 1960, reaching 67, for anyone born in 1960 or later, full retirement benefits are payable at age 67. Baby Boomers and those nearing retirement are likely aware that Social Security alone will not provide a comfortable retirement, so passive income can be a significant help in increasing overall monthly income. Five high-yield monthly pay stocks are among the best investment ideas for those looking to generate safe and reliable passive income to supplement Social Security and pension income. --> --> 24/7 Wall St. Key Points Seniors can likely expect another year of 2.6% cost-of-living adjustment (COLA). Monthly pay stocks are a great way to supplement Social Security with passive income. Extra income plus the tax breaks from the Big Beautiful Bill are big wins for Boomers. Are monthly pay dividend stocks a good fit for you? Why not schedule a meeting with a financial advisor near you and find out? Click here and get started today. (Sponsored) --> --> Most stocks pay quarterly dividends, which is fine for many shareholders who reinvest dividends. However, many investors rely on dividends as part of a passive income stream, and getting a monthly dividend payout is more beneficial. Typically, real estate investment trusts (REITs), business development companies, and closed-end funds are among the investment vehicles that pay distributions monthly. We screened our 24/7 Wall St. monthly dividend stock research database, looking for safe ideas that Boomers can own with confidence. Five top companies hit our screens, and all have a Buy rating from top Wall Street firms. Why we recommend monthly income stocks A monthly check from your stock portfolio makes sense for most people with bills and expe

Boomers Are Grabbing 5 High-Yield Monthly Pay Stocks to Supplement Social Security

TYSONS, Va.--(BUSINESS WIRE)--Alarm.com (Nasdaq: ALRM), the leading platform for intelligently connected properties, today announced the ADC-V516, a compact and budget-friendly indoor Wi-Fi camera. As part of Alarm.com's professional security ecosystem, the ADC-V516 makes advanced performance and trusted reliability accessible for more households and small businesses. The ADC-V516 pairs 1080p HDR video with intelligent video analytics, two-way audio, and proactive deterrence tools—all fully int.

Alarm.com Brings Pro-Grade Video Security to More Homes and Businesses with the New ADC-V516 Indoor Wi-Fi Camera

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.256 per common share. The monthly dividend reflects an annualized dividend amount of $3.072 per common share, representing a 2.4% increase over the annualized dividend amount of $3.00 per common share from the third quarter of 2024. The dividend is payable October 14, 2025 to stockholders o.

Agree Realty Declares Monthly Common and Preferred Dividends

Dividend stocks are the cornerstone of a great investment portfolio. The right mix of dividend stocks can provide security for your funds as well as a growing passive income stream, which is why they are even more important for retirees.

10 Dividend Stocks to Hold for the Next 10 Years

LAUSANNE, Switzerland , Sept. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 29,700 of the Company's common shares to two new employees on September 2, 2025 (each, a "Grant").

LAUSANNE, Switzerland , Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:10 a.m. ET. A webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com.

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

LAUSANNE, SWITZERLAND , OCT. 27, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED PARTICIPATION IN THREE UPCOMING INVESTOR CONFERENCES IN NOVEMBER: STEPHENS BIOTECHNOLOGY VIRTUAL FIRESIDE CHATS 2025DATE: NOVEMBER 3, 2025 PRESENTATION TIME: 12:00 P.M. ET FORMAT: FIRESIDE CHATSPEAKER: AMEET MALLIK, CHIEF EXECUTIVE OFFICERLOCATION: VIRTUAL THERE WILL NOT BE A REPLAY OR TRANSCRIPT OF THE CALL.

ADC THERAPEUTICS TO PRESENT AT NOVEMBER INVESTOR CONFERENCES

SHANGHAI & CAMBRIDGE, MASS.--(BUSINESS WIRE)--ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED UPDATED DATA FROM THE GLOBAL PHASE 1 CLINICAL TRIAL OF ZOCILURTATUG PELITECAN (ZOCI), FORMERLY KNOWN AS ZL-1310, (NCT06179069) DEMONSTRATING ROBUST AND DURABLE RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC). THIS DATA WILL BE PRESENTED AS AN ORAL PRESENTATION AND WAS INCLUDED AS PART OF THE PRESS PROGRAM AT THE AACR-NCI-EORTC INTERNATIONAL CON.

ZAI LAB ANNOUNCES UPDATED PHASE 1 DATA FOR ZOCILURTATUG PELITECAN (FORMERLY ZL-1310), DEMONSTRATING POTENTIAL AS A FIRST-IN-CLASS/BEST-IN-CLASS DLL3-TARGETED ADC FOR SMALL CELL LUNG CANCER, AND INITIATION OF GLOBAL PHASE 3 REGISTRATIONAL STUDY

MONTREAL, QUEBEC--(NEWSFILE CORP. - OCTOBER 23, 2025) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("DEFENCE" OR THE "COMPANY"), A LEADING BIOTECHNOLOGY COMPANY SPECIALIZED IN DRUG DELIVERY TECHNOLOGIES, IS PLEASED TO ANNOUNCE THAT IT WILL PRESENTNEW SCIENTIFIC DATA HIGHLIGHTING THE PERFORMANCE OF ITS ACCUM TECHNOLOGYIN ENHANCING THE EFFICACY OF ANTIBODY-DRUG CONJUGATES (ADCS) AT THE16TH WORLD ADC CONFERENCEIN SAN DIEGO, CA, USA. DEFENCE'S PROPRIETARYACCUM PLATFORMIS ENGINEERED TO IMPROVE INTRACELLULAR DELIVERY AND ENDOSOMAL ESCAPE OF THERAPEUTIC PAYLOADS, ADDRESSING A CRITICAL LIMITATION OF CURRENT ADCS AND ENABLING HIGHER POTENCY WITH REDUCED OFF-TARGET TOXICITY.

DEFENCE TO PRESENT NEW SCIENTIFIC DATA ON ITS ADC-ENHANCING ACCUM TECHNOLOGY AT THE WORLD ADC CONFERENCE IN SAN DIEGO, USA, NOVEMBER 4-5, 2025

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025. ALL PER SHARE AMOUNTS INCLUDED HEREIN ARE ON A DILUTED PER COMMON SHARE BASIS UNLESS OTHERWISE STATED. THIRD QUARTER 2025 FINANCIAL AND OPERATING HIGHLIGHTS: INVESTED APPROXIMATELY $451 MILLION IN 110 RETAIL NET LEASE PROPERTIES ACROSS ALL THREE EXTERNAL GROWTH PLATFORMS COMMENCED FIVE DEVELOPMENT OR DEVELOPER FUNDING PLATFORM (DFP) PROJECTS.

AGREE REALTY CORPORATION REPORTS THIRD QUARTER 2025 RESULTS

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.262 PER COMMON SHARE, REPRESENTING A 2.3% MONTH-OVER-MONTH INCREASE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.144 PER COMMON SHARE, REPRESENTING A 3.6% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.036 PER COMMON SHARE FROM THE FOURTH QUARTER OF 2024. THE DIVID.

AGREE REALTY DECLARES INCREASED MONTHLY COMMON DIVIDEND

LAUSANNE, SWITZERLAND , OCT. 13, 2025 /PRNEWSWIRE/ --ADC THERAPEUTICS SA(NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT HAS ENTERED INTO SECURITIES PURCHASE AGREEMENTS FOR THE SALE OF ITS EQUITY SECURITIES TO CERTAIN INSTITUTIONAL INVESTORS IN A $60.0 MILLION PRIVATE INVESTMENT IN PUBLIC EQUITY ("PIPE") FINANCING. IN THE PIPE, ADC THERAPEUTICS IS SELLING 11.3 MILLION COMMON SHARES AT $4.00 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE 3.8 MILLION COMMON SHARES AT $3.90 PER PRE-FUNDED WARRANT, WHICH IS THE PRICE PER COMMON SHARE IN THE PIPE MINUS THE EXERCISE PRICE OF CHF 0.08 PER PRE-FUNDED WARRANT.

ADC THERAPEUTICS ANNOUNCES $60 MILLION PRIVATE PLACEMENT

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DAIICHI SANKYO (TSE: 4568) WILL PRESENT NEW CLINICAL RESEARCH ACROSS ITS DXD ANTIBODY DRUG CONJUGATE (ADC) PORTFOLIO WITH FOUR LATE-BREAKING PRESENTATIONS FROM MORE THAN 20 ABSTRACTS AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (#ESMO25) CONGRESS. DATA AT ESMO WILL SPOTLIGHT THE COMPANY'S ADVANCES TOWARDS CREATING NEW STANDARDS OF CARE FOR PATIENTS WITH BREAST CANCER, INCLUDING BACK-TO-BACK PRESENTATIONS DURING PRESIDENTIAL SYMPOSIUM I FEATURIN.

DAIICHI SANKYO CONTINUES TO TRANSFORM STANDARDS OF CARE FOR PATIENTS WITH THREE LANDMARK BREAST CANCER TRIALS AND ADDITIONAL DATA ACROSS INDUSTRY-LEADING ADC PORTFOLIO AT ESMO

BOSTON AND LONDON, OCT. 09, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT HAS FILED TWO NEW PROVISIONAL PATENT APPLICATIONS WITH THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO). THE FIRST APPLICATION INCLUDES CLAIMS PROTECTING AKARI'S NOVEL IMMUNO-ONCOLOGY PAYLOAD, PH1 (A NOVEL THAILANSTATIN ANALOG), AND ITS SPLICEOSOME MODULATORY MECHANISM OF ACTION, WHICH IS EXPECTED TO PROVIDE A THERAPEUTIC BENEFIT BY ACTIVATING THE HOST IMMUNE SYSTEM IN THE FIGHT AGAINST CANCER. THE SECOND PATENT FILING INCLUDES CLAIMS FOR A COMBINATION THERAPY OF PH1 PIPELINE ADCS WITH OTHER IMMUNO-ONCOLOGY DRUGS THAT ALLEVIATE CHECKPOINT INHIBITION AND HAVE DEMONSTRATED SYNERGY WITH IMMUNE CHECKPOINT INHIBITORS (ICIS) IN PRECLINICAL MODELS. THESE NEW PATENT APPLICATIONS ARE PART OF A GROWING PATENT PORTFOLIO STRATEGY DESIGNED TO FURTHER EXTEND AKARI'S PROPRIETARY POSITION WITH RESPECT TO THE COMPANY'S NOVEL PH1 PAYLOAD. THESE FILINGS ALSO BUILD UPON AKARI'S RECENT PROVISIONAL PATENT FILING IN LATE SEPTEMBER COVERING THE USE OF AKARI'S ADC PLATFORM TO TARGET CANCER BY MODULATING ALTERNATIVE SPLICING DRIVERS WITHIN CANCER CELLS.

AKARI THERAPEUTICS FILES TWO NEW PATENTS FOR IMMUNO-ONCOLOGY MODE OF ACTION FOR NOVEL ADC PLATFORM UTILIZING SPLICEOSOME MODULATING PAYLOAD PH1

CATALENT GAINS GLOBAL RIGHTS TO EVALUATE CERTEPETIDE AND ITS ANALOGS FOR USE AS SMARTAG PAYLOADS ACROSS MULTIPLE ADCS DESIGNED TO ADDRESS DIFFICULT-TO-TREAT DISEASES

LISATA THERAPEUTICS AND CATALENT ANNOUNCE GLOBAL ANTIBODY-DRUG CONJUGATE (ADC) LICENSE AGREEMENT

MILPITAS, CALIF.--(BUSINESS WIRE)-- #ADC--OMNI DESIGN TECHNOLOGIES, A LEADING PROVIDER OF HIGH-PERFORMANCE, LOW-POWER WIDEBAND SIGNAL PROCESSING SOLUTIONS, TODAY ANNOUNCED THE TAPE OUT OF ITS NEW ODT-ADS-7B64G-3T, AN ULTRA-HIGH-SPEED 64 GSPS SWIFT ANALOG-TO-DIGITAL CONVERTER (ADC) SUPPORTING 7- AND 8-BIT OUTPUT MODES, DESIGNED IN TSMC'S 3NM PROCESS. THIS TIME-INTERLEAVED ADC PROVIDES THE BREAKTHROUGH SPEED AND PERFORMANCE REQUIRED FOR THE NEXT GENERATION OF HIGH-SPEED DATA COMMUNICATIONS, INCLUDING.

OMNI DESIGN TECHNOLOGIES TAPES OUT ULTRA-HIGH-SPEED 64GSPS ADC ON TSMC N3 PROCESS

LAUSANNE, SWITZERLAND , OCT. 1, 2025 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 162,000 OF THE COMPANY'S COMMON SHARES TO FOUR NEW EMPLOYEES ON OCTOBER 1, 2025 (EACH, A "GRANT"). THE GRANTS WERE OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEES' EMPLOYMENT.

ADC THERAPEUTICS MAKES GRANTS TO NEW EMPLOYEES UNDER INDUCEMENT PLAN

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT IT WILL RELEASE ITS THIRD QUARTER 2025 OPERATING RESULTS AFTER THE MARKET CLOSES ON TUESDAY, OCTOBER 21, 2025. A CONFERENCE CALL TO DISCUSS THE COMPANY'S OPERATING RESULTS IS SCHEDULED FOR WEDNESDAY, OCTOBER 22, 2025 AT 9:00 AM ET. INTERESTED PARTIES AND SHAREHOLDERS MAY ACCESS THE CALL VIA TELECONFERENCE OR WEBCAST: TELECONFERENCE: USA TOLL FREE (800) 715-9871 INTERNATIONAL (646) 307-19.

AGREE REALTY ANNOUNCES THIRD QUARTER 2025 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

DATA HIGHLIGHTS ABILITY OF AKARI'S ADC PAYLOAD, PH1, TO SUPPRESS THE LEVELS OF THE AR-V7 RECEPTOR THAT IS RESPONSIBLE FOR DRIVING HORMONE REFRACTORY PROSTATE CANCER PROGRESSION

AKARI THERAPEUTICS' PRECLINICAL DATA DEMONSTRATES THE POTENTIAL OF ITS NOVEL ADC SPLICEOSOME MODULATING PAYLOAD, PH1

BOSTON AND LONDON, SEPT. 17, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT HAS FILED A PROVISIONAL PATENT APPLICATION WITH THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) COVERING THE COMPANY'S ANTIBODY DRUG CONJUGATE (ADC) PLATFORM USING AKARI'S SPLICEOSOME PAYLOAD PH1 FOR TREATING CANCER BY MODULATING ALTERNATIVE SPLICING WITHIN CANCER CELLS. THIS PATENT APPLICATION REPRESENTS A NEW PATENT FAMILY TO FURTHER EXTEND AKARI'S PROPRIETARY POSITION WITH RESPECT TO THE COMPANY'S NOVEL PAYLOAD, PH1 (A NOVEL THAILANSTATIN ANALOG).

AKARI THERAPEUTICS ANNOUNCES FILING FOR NEW PATENT FOR NOVEL ADC PLATFORM UTILIZING SPLICEOSOME PAYLOAD PH1 FOR THE TREATMENT OF CANCER

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.256 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE, REPRESENTING A 2.4% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.00 PER COMMON SHARE FROM THE THIRD QUARTER OF 2024. THE DIVIDEND IS PAYABLE OCTOBER 14, 2025 TO STOCKHOLDERS O.

AGREE REALTY DECLARES MONTHLY COMMON AND PREFERRED DIVIDENDS

TYSONS, VA.--(BUSINESS WIRE)--ALARM.COM (NASDAQ: ALRM), THE LEADING PLATFORM FOR INTELLIGENTLY CONNECTED PROPERTIES, TODAY ANNOUNCED THE ADC-V516, A COMPACT AND BUDGET-FRIENDLY INDOOR WI-FI CAMERA. AS PART OF ALARM.COM'S PROFESSIONAL SECURITY ECOSYSTEM, THE ADC-V516 MAKES ADVANCED PERFORMANCE AND TRUSTED RELIABILITY ACCESSIBLE FOR MORE HOUSEHOLDS AND SMALL BUSINESSES. THE ADC-V516 PAIRS 1080P HDR VIDEO WITH INTELLIGENT VIDEO ANALYTICS, TWO-WAY AUDIO, AND PROACTIVE DETERRENCE TOOLSALL FULLY INT.

ALARM.COM BRINGS PRO-GRADE VIDEO SECURITY TO MORE HOMES AND BUSINESSES WITH THE NEW ADC-V516 INDOOR WI-FI CAMERA

LAUSANNE, SWITZERLAND , SEPT. 2, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 29,700OF THE COMPANY'S COMMON SHARES TO TWO NEW EMPLOYEES ON SEPTEMBER 2, 2025 (EACH, A "GRANT").

LAUSANNE, SWITZERLAND , AUG. 27, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT AMEET MALLIK, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE 2025 ON WEDNESDAY, SEPTEMBER 3, 2025, AT 9:10 A.M. ET. A WEBCAST OF THE PRESENTATION WILL BE AVAILABLE VIA THE EVENTS & PRESENTATIONS PAGE IN THE INVESTORS SECTION OF ADC THERAPEUTICS' WEBSITE,IR.ADCTHERAPEUTICS.COM.

Agree Realty

ADC

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC